The terms, per the grant. On January 31, 2023, Nanjing Legend Biotech was issued US11564945B2, covering a chimeric antigen receptor and its use. The CPC tags — A61K 35/17 (lymphocyte therapy), C07K 14/7051 (T-cell receptor chains), C07K 16/30/32 (the targeting binders), C12N 15/62 (fusion constructs) — describe an engineered receptor that redirects T cells against a tumor antigen.
Why CAR IP anchors big deals: a chimeric antigen receptor is an engineered, multi-domain construct — binder, hinge, transmembrane, signaling domains — and the specific combination is protectable. Demonstrated clinical activity in blood cancers turned CAR constructs into the assets behind some of the largest cell-therapy partnerships, where the construct IP underwrites the upfront and milestones.
The structure point: a CAR deal is priced on the construct and its target. For a model, the binder defines the addressable indication, while the signaling architecture can be reused across targets. Naming the grant is how you see which domains a deal actually controls and how broad the construct's reuse potential is.
What the grant does not promise: a clinical result, an approval, or freedom from competing CAR and binder estates. It is an exclusivity claim on a specific receptor construct within a heavily patented field.
The takeaway: when a cell-therapy deal crosses the desk, read the CAR construct and target claims as the load-bearing assets. Legend Biotech's January 2023 CAR grant is a dated, concrete example of the construct IP behind major cell-therapy partnerships.